Postdoctoral positions are available to study molecular mechanisms associated with therapeutic response and resistance in non-small cell lung cancer (NSCLC) in the laboratory of John V. Heymach, MD, PhD at The University of Texas MD Anderson Cancer Center in Houston, TX. The lab is largely interested in the development of rationale treatment strategies for KRAS, EGFR, and HER2 mutant NSCLC with a focus on overcoming resistance to targeted therapies, identifying targetable metabolic adaptations, and enhancing response to immunotherapy. Applicants with experience in any of these areas are encouraged to apply and provide three professional references.

Trainees will perform translational research involving molecular biology approaches (such as CRISPR/Cas technology, Western blotting, ELISA, immunohistochemistry), in vitro assays (such as drug screening, flow cytometry, development of resistant cell lines, metabolic profiling) and in vivo experiments using xenograft, syngeneic and genetically engineered mouse models of lung cancer. Trainees will present their findings at regular lab meetings, departmental seminars, and national conferences. Trainees will submit their findings for publication in peer-reviewed scientific journals.

Applications are invited from qualified individuals, interested in working in a translational research lab; with a PhD and/or MD. Preferred candidate should have less than 2 years of prior postdoctoral experience with background in mouse models studying cancer biology, cell biology, molecular biology, or immunology and be highly motivated to pursue an independent career in biomedical research.

JOB KNOWLEDGE AND SKILLS:
- Enthusiastic, highly self-motivated candidate, with the ability to function independently.
- A strong background in cell and molecular biology, immunology, or metabolic signaling.
- Dedication to basic research, a true "drive", is important.
- Prior experience with studies involving mice is preferred.
- Command of written and spoken English language.
- Prior publication record.